Marshall Wace LLP Buys 38,984 Shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Marshall Wace LLP boosted its position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 202.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 58,260 shares of the company’s stock after purchasing an additional 38,984 shares during the quarter. Marshall Wace LLP owned about 0.21% of ClearPoint Neuro worth $314,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. XTX Topco Ltd boosted its holdings in shares of ClearPoint Neuro by 11.6% in the second quarter. XTX Topco Ltd now owns 13,010 shares of the company’s stock worth $70,000 after buying an additional 1,353 shares during the last quarter. Renaissance Technologies LLC raised its stake in ClearPoint Neuro by 562.6% during the 2nd quarter. Renaissance Technologies LLC now owns 169,700 shares of the company’s stock worth $915,000 after acquiring an additional 144,088 shares during the period. Rinkey Investments bought a new stake in shares of ClearPoint Neuro during the second quarter valued at approximately $307,000. Legato Capital Management LLC raised its position in shares of ClearPoint Neuro by 21.6% during the second quarter. Legato Capital Management LLC now owns 158,968 shares of the company’s stock valued at $857,000 after buying an additional 28,227 shares during the last quarter. Finally, AWM Investment Company Inc. bought a new stake in shares of ClearPoint Neuro during the first quarter valued at approximately $894,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CLPT. B. Riley assumed coverage on shares of ClearPoint Neuro in a research report on Thursday, July 25th. They set a “buy” rating and a $10.00 price objective on the stock. Lake Street Capital lifted their price objective on shares of ClearPoint Neuro from $11.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th.

ClearPoint Neuro Price Performance

CLPT stock opened at $11.61 on Friday. The company has a market capitalization of $320.44 million, a P/E ratio of -16.35 and a beta of 1.10. The business has a 50-day moving average price of $11.25 and a 200 day moving average price of $7.88. ClearPoint Neuro, Inc. has a 1-year low of $4.05 and a 1-year high of $13.47.

ClearPoint Neuro (NASDAQ:CLPT) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.03. The firm had revenue of $7.86 million during the quarter, compared to analyst estimates of $7.50 million. ClearPoint Neuro had a negative net margin of 64.06% and a negative return on equity of 64.23%. During the same period last year, the firm posted ($0.29) EPS. On average, analysts anticipate that ClearPoint Neuro, Inc. will post -0.65 earnings per share for the current fiscal year.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.